1stOncology™: Cancer Intelligence Service – Page 12625 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Rigel to Present at the 38th Annual J.P. Morgan Healthcare Conference

On January 9, 2020 Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) reported that Raul Rodriguez, the company’s president and CEO, is scheduled to present a company overview at the 38th Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2020 at 7:30am PT in San Francisco, CA (Press release, Rigel, JAN 9, 2020, View Source [SID1234552956]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

To access the live and subsequently archived webcast, go to the Investor Relations section of the company’s website at www.rigel.com. Please connect to Rigel’s website several minutes prior to the start of the live webcast to ensure adequate time for any software download that may be necessary.

Adicet Bio to Present at J.P. Morgan Healthcare Conference

On January 9, 2020 Adicet Bio, Inc., a biopharmaceutical company focused on the development of allogeneic cell therapies for cancer using innovative gamma delta T cells, reported that the company will present at the 38th Annual J.P. Morgan Healthcare Conference (Press release, Adicet Bio, JAN 9, 2020, View Source [SID1234552955]).

Anil Singhal, Ph.D., President and Chief Executive Officer of Adicet Bio, will provide a company overview on Thursday, January 16, 2020, at 7:30am PT.

Insmed to Present at the 38th Annual J.P. Morgan Healthcare Conference

On January 9, 2020 Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, reported that Will Lewis, Chairman and Chief Executive Officer of Insmed, will present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 16, 2020 at 9:00 a.m. PT (Press release, Insmed, JAN 9, 2020, View Source [SID1234552954]).

The presentation will be webcast live and can be accessed by visiting the investor relations section of the company’s website at www.insmed.com. The webcast will be archived for a period of 30 days following the conclusion of the live event.

IsoPlexis Closes Additional $20 Million Financing to Continue Commercial Expansion of Single-Cell Systems

On January 9, 2020 IsoPlexis, the leader in single-cell functional proteomics, has reported that it has raised an additional $20 million in its Series C financing, bringing the entire Series C round to $45 million (Press release, IsoPlexis, JAN 9, 2020, View Source [SID1234552953]). The funding will continue to drive the global commercial expansion of its IsoLight single-cell proteomic analysis platform. The recent financing was led by Northpond Ventures, along with participation from existing investors.

IsoPlexis has recently expanded its operational, manufacturing, and commercial team across the US, Europe, and Asia, with 130 employees. The IsoLight single-cell system is used globally by leading biotech, pharma, and academic medical centers to solve critical challenges in cell therapy, cancer immunology, and inflammatory disease.

"We are excited to continue our partnership with our investor base and to broaden our commercial impact globally with our single-cell proteomic systems. Our leadership in providing meaningful cellular insights to the world of cancer immunology has rapidly translated to broad uptake for our solutions, and we are looking forward to expanding our work with customers and building upon recent progress," said Sean Mackay, CEO and Co-Founder of IsoPlexis.

"IsoPlexis is providing much needed solutions to significant challenges in cancer immunology and engineered cellular therapy discovery and development," said Sharon Kedar, Co-Founder and Partner of Northpond Ventures. "We are excited to continue partnering with IsoPlexis on these efforts to transform personalized medicine."

In 2020, IsoPlexis will continue to expand its applications and release innovative products addressing high need research areas for its existing and future customer base, including products that address innate & myeloid function, tumor cell signaling, and other high need areas.

Cannabics Pharmaceuticals Announces Cannabigerol (CBG) Shown to Have Anti-tumor Properties

On January 9, 2020 Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, reported that in a pre-clinical study held at the company’s High Throughput Screening (HTS) lab facilities in Israel, preliminary findings show that the cannabinoid Cannabigerol (CBG) was shown to have a greater anti-tumor effect on human stomach and bone cancer cell lines compared to CBGA, the acidic form of the compound (Press release, Cannabics Pharmaceuticals, JAN 9, 2020, View Source [SID1234552950]).

CBG is a non-psychoactive cannabinoid found in minute quantities in the raw cannabis plant. Also known as the "mother" cannabinoid, other cannabinoids such as THC, CBD, CBN and CBC are synthesized from CBG. It is anecdotally known to show promise in having anti-inflammatory qualities and may act as an antibacterial agent.

In the current experiment, the HTS platform was utilized to screen the necrotic effects of both CBG & CBGA on various types of cancer cell lines. Interestingly, CBG was found to induce necrotic effects while CBGA had no such effect.

These findings further support previous research performed by the company, which has consistently shown differential anti-tumor effects when using a variety of cannabinoids on human cancer cells, derived from both fresh biopsies and cell lines.

These preliminary findings could allow Cannabics Pharmaceuticals to offer in the future, pending further research, a more extensive and thorough personalized report for patients advising them on cannabinoid medicine therapy protocols in order to maximize positive outcomes.

Dr. Yaakov Waksman, the company’s Head of Cannabidiol Research, said: "CBG is gaining a lot of interest as of late by the scientific community due to its potential therapeutic properties. The recent preliminary findings from our research team illustrate how purified cannabinoids can potentially yield anti-tumor activity and enable us to examine the entourage effect of botanical extracts versus the purified compounds. We are excited by these preliminary findings and plan to perform additional experiments in the near future to further support them."